- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06873048
Short-term Study of Two Soft Contact Lenses in Wearers With Low Astigmatism
April 6, 2026 updated by: CooperVision International Limited (CVIL)
Short-term Study of Myday Sphere and Myday Toric Lenses in Existing Spherical Soft Contact Lenses Wearers With Low Astigmatism (Pacific)
The primary objective of the study is to evaluate and compare the performance of two soft contact lens.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The primary objective of the study is to evaluate and compare the performance of two different soft contact lens in existing spherical soft contact lens (CL) wearers with low levels of refractive astigmatism over a 2-week wear period.
Study Type
Interventional
Enrollment (Actual)
32
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Waterloo, Ontario, Canada, N2L 3G1
- School of Optometry & Vision Science
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- At least 17 years and no more than 42 years of age.
- Have read and signed the study consent form.
- Are willing and able to follow instructions and maintain the appointment schedule.
- Are habitual wearer of spherical soft contact lenses (not toric or multifocal design), any brand and any replacement frequency.
- Are willing to wear the study contact lenses for 6 days a week while in this study and on three days (day 1, Day 7 and Day 13) for at least 12 hours.
- Are willing to provide a contact email and telephone number and to use a device that allows them to respond to a short online questionnaire every 3 hours on days 1, 7 and 13 of each lens arm, while wearing one of the 2 study lenses.
- Are non-presbyopic i.e. no requirement for a reading addition for routine daily tasks (self report).
- Have astigmatism of either -0.50, -0.75, -1.00 or -1.25 DC in each eye by subjective sphero-cylindrical refraction.
- Achieves at least 0.10 LogMAR in each eye by subjective sphero-cylindrical refraction.
- Can be fit with available study contact lens powers of between +6.00 to -10.00 DS.
- Demonstrate an acceptable fit with the study contact lenses.
Exclusion Criteria:
- Are participating in any concurrent clinical interventional study.
- Have worn rigid contact lenses in the last 3 months.
- Have worn soft toric contact lenses in the past 3 months.
- Have any known active ocular disease or allergies and/or infection.
- Have clinically significant biomicroscopy findings or have an ocular condition that contraindicate contact lens wear.
- Have a systemic condition that in the opinion of the investigator may affect a study outcome variable or contraindicate wearing soft contact lenses.
- Are using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable or contraindicate wearing soft contact lenses.
- Have known sensitivity to the diagnostic sodium fluorescein to be used in the study.
- Have undergone refractive error surgery or intraocular surgery.
- Are an employee of the Centre for Ocular Research & Education directly involved in this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Control Contact Lens (stenfilcon A Sphere)
All participants will wear Control Contact Lens for one week (Period 1).
|
One week of wear
|
|
Experimental: Test Contact Lens (stenfilcon A Toric)
All participants will wear Test Contact Lens for one week (Period 2).
|
One week of wear
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Contact Lens Comfort
Time Frame: Day 1 (day after dispense), Day 7 and Day 13 at 12 hours contact lens wear
|
Contact lens comfort will be measured on the scale of 0-100 where, (0=worst and 100=best)
|
Day 1 (day after dispense), Day 7 and Day 13 at 12 hours contact lens wear
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Lyndon Jones, PhD,FCOptom, Centre for Ocular Research and Education
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 26, 2025
Primary Completion (Actual)
July 11, 2025
Study Completion (Actual)
July 11, 2025
Study Registration Dates
First Submitted
March 7, 2025
First Submitted That Met QC Criteria
March 7, 2025
First Posted (Actual)
March 12, 2025
Study Record Updates
Last Update Posted (Actual)
April 8, 2026
Last Update Submitted That Met QC Criteria
April 6, 2026
Last Verified
April 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CV-24-42
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.